Study Summary
The main purpose of this study is to explore the sequential therapeutic effect and evaluate the safety of anti-CD19 or anti-CD20 CAR-T cells briging HSCT in the treatment of relapse/refractory B cell malignancies.
Want to learn more about this trial?
Request More InfoInterventions
CD19 or CD20 CAR T cells briging HSCTBIOLOGICAL
Patients will receive a one-week regimen of chemotherapy consisting of fluid arabise and cyclophosphamide aimed to deplete the lymphocytes. One week later, patients are intravenously infused autologous anti-CD19 or anti-CD20 CAR T cells.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Southwest Hospital of Third Millitary Medical University | Chongqing | Chongqing Municipality | China |